Monoclonal Antibody

Antibody cocktail shown to neutralise SARS-CoV-2 variants of concern

28 April 2021 | By Victoria Rees (Drug Target Review)

A new antibody cocktail made from three mAbs neutralised several SARS-CoV-2 variants in pre-clinical studies.

Researchers identify antibodies with potent effects against malaria

8 March 2021 | By Victoria Rees (Drug Target Review)

Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.

Sino Biological Inc.

Experimental mAb subdues type 1 diabetes in laboratory mice

23 February 2021 | By Victoria Rees (Drug Target Review)

A monoclonal antibody given to mice reversed type 1 diabetes by suppressing the actions of glucagon, a study has shown.

Advancing neutralising antibody therapies for COVID-19

17 February 2021 | By Hannah Balfour (Drug Target Review)

In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody candidate ABP 300 is currently in Phase II/III trials.

Novel antibody candidate could offer pan-coronavirus protection

26 January 2021 | By Hannah Balfour (Drug Target Review)

The lead candidate, ADG2, was able to neutralise SARS-CoV and various strains of SARS-CoV-2, including those that are resistant to currently available antibody treatments.

Antibody effector functions are key to combatting COVID-19, finds study

23 November 2020 | By Hannah Balfour (Drug Target Review)

Rodent studies show that using antibodies with different targets and modes of action in combination is more effective at preventing and treating COVID-19.

Anti-C5aR antibody shows promise as immuno-oncology treatment

12 November 2020 | By Victoria Rees (Drug Target Review)

Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.

Screening process may enhance mAb drug development, say scientists

4 August 2020 | By Victoria Rees (Drug Target Review)

Screening potential monoclonal antibody (mAb) drugs on their colloidal stability could eliminate mAbs that do not respond efficiently in solution.

Protective antibodies identified for rare polio-like disease in children

6 July 2020 | By Hannah Balfour (Drug Target Review)

Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.

Antibodies against viral disease: highlighting technologies behind COVID-19 antibody therapy

4 June 2020 | By Shalom Gurjar (OXGENE)

Amid the rush to develop an effective vaccine against COVID-19, antibody therapy has become a major strategy to ameliorate and treat cases of severe disease. Armed with the capacity to neutralise pathogens and orchestrate the immune system, promising antibody candidates for multiple viral indications, including HIV, continue to emerge. Technology…

Antibodies allow for a targeted approach to cancer therapy

26 March 2020 | By Nikki Withers (Drug Target Review)

Cancer can be an immovable beast, tenacious in its numerous mechanisms to thrive and grow. However, the healthcare industry has an ever-expanding arsenal of therapies designed to thwart it, with variable levels of success. Nikki Withers speaks to Dr Jill O’Donnell-Tormey, CEO and Director of Scientific Affairs at the Cancer…

Rebalancing the immune system to treat autoimmune disease

2 March 2020 | By Hannah Balfour (Drug Target Review)

Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.

Novel antibody breaks bacterial biofilms and prevents sepsis in mice

2 March 2020 | By Victoria Rees (Drug Target Review)

A new monoclonal antibody has been discovered which disassociates bacterial biofilms and stops bacteria from entering into circulation has been tested in mice.

Antibody therapeutic candidate could be used to treat autoimmune diseases

20 December 2019 | By Victoria Rees (Drug Target Review)

Researchers have used a drug candidate to block a receptor that contributes to the development of autoimmune disease which could be a potential treatment.